(Q80119050)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17417660%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

title

Early recovery of aggressive cytotoxic cells and improved immune resurgence with post-transplant immunotherapy for multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17417660%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference

Meehan KR

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17417660%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Wu J

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17417660%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Bengtson E

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17417660%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Hill J

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17417660%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Ely P

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17417660%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Szczepiorkowski Z

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17417660%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Kendall M

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17417660%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Ernstoff MS

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17417660%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

publication date

9 April 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17417660%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

28 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17417660%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17417660%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17417660%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

page(s)

695-703

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17417660%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705665

28 December 2019

exact match

0 references

cites work

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

Myeloma-reactive allospecific cytotoxic T lymphocytes lyse target cells via the granule exocytosis pathway.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

Ex vivo induction of multiple myeloma–specific cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

Interleukin-2-activated hematopoietic stem cell transplantation for breast cancer: investigation of dose level with clinical correlates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

A pilot study evaluating interleukin-2-activated hematopoietic stem cell transplantation for hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

Post-bone marrow transplant use of immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

Immunotherapy with interleukin-2 and alpha-interferon after IL-2-activated hematopoietic stem cell transplantation for breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

Prognostic analysis of pre-transplant peripheral T-cell levels in patients receiving an autologous hematopoietic progenitor-cell transplant.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

Regression and inhibition of sarcoma growth by interference with a radiosensitive T-cell population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

Systemic therapy of melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

Treatment with interleukin-2 (IL-2) and interferon (IFN(alpha 2b)) after autologous bone marrow or peripheral blood stem cell transplantation in onco-hematological malignancies with a high risk of relapse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021

Immunologic profiles of effector cells and peripheral blood stem cells mobilized with different hematopoietic growth factors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705665

7 January 2021